证券代码：000534 证券简称：万泽股份 公告编号:2026-008 万泽实业股份有限公司 关于控股股东持股比例变动达到 1%的公告 公司于 2026 年 1 月 6 日披露了《关于控股股东减持股份的预披露公告》 （公告编号：2026-002），万泽集团计划在 2026 年 1 月 27 日至 2026 年 4 月 26 日通过深圳证券交易所证券交易系统的集中竞价交易或大宗交易方式 减持本公司股份不超过 8,000,000 股。 二、控股股东持股变动的具体情况 公司近日收到万泽集团《关于持股变动比例超过 1%的通知函》：自 2026 年 2 月 3 日至 2026 年 2 月 4 日，上述可交换公司债券的债券持有人累计换 股 1,687,795 股，加之万泽集团于 2026 年 2 月 3 日至 2026 年 2 月 4 日通过 深圳证券交易所证券交易系统的集中竞价交易方式减持本公司股份250,000 股，导致万泽集团及其一致行动人合计持有公司股份数量减少 1,937,795 股， 持股比例由 26.32%降至 25.94%，持股比例变动达到 1%。现将相关情况公 告如下： | 1．基本情况 | | | | ...

Core Viewpoint - Wanze Group's exchangeable bonds have entered the conversion period, leading to a reduction in shareholding percentage due to stock conversion and share reduction activities [1] Group 1: Shareholding Changes - As of February 3-4, 2026, bondholders converted a total of 1.687795 million shares [1] - Wanze Group reduced its holdings by 250,000 shares during the same period, resulting in a total reduction of 1.937795 million shares for Wanze Group and its concerted parties [1] - The shareholding percentage of Wanze Group decreased from 26.32% to 25.94%, reflecting a change of 1% [1] Group 2: Planned Share Reduction - Wanze Group originally planned to reduce its holdings by no more than 8 million shares between January 27 and April 26, 2026 [1] - As of February 4, 2026, Wanze Group has cumulatively reduced its holdings by 1.733 million shares [1]

Summary of Conference Call Records Industry Overview - The focus is on the domestic large aircraft sector, which is experiencing significant growth and investment interest. The market is characterized by a contradiction between the long-term potential and short-term delivery challenges of domestic large aircraft [1][2]. Key Points and Arguments - **Bottleneck Breakthroughs**: The industry is entering a phase where critical bottlenecks, particularly in engines and onboard equipment, are being addressed. This is expected to accelerate the delivery of domestic large aircraft [1][2]. - **Market Sentiment**: There is a prevailing belief that the delivery pace of domestic large aircraft is slow, yet the long-term market potential remains vast. The resolution of bottlenecks is anticipated to lead to a steep change in expectations [1]. - **Catalysts for Growth**: Recent developments, such as the European Union Aviation Safety Agency (EASA) beginning flight evaluations for the C919 in Shanghai, are expected to enhance the global competitiveness of China's commercial aircraft [1]. Core Companies Mentioned - **Major Players**: - Two major companies: AVIC (中航机载) and Aero Engine Corporation of China (航发动力) are highlighted as key players in the engine and onboard equipment sectors [2]. - Four additional companies: AVIC Technology (航发科技), Jiangxi Aircraft Equipment (江航装备), Huayin Technology (华秦科技), and Wanzhe Co. (万泽股份) are also noted for their roles in the industry [1][2]. Additional Important Information - **Engine Development**: The Changjiang 1000 engine has entered the airworthiness certification phase, progressing faster than expected. This is crucial for addressing the backlog of main engine orders due to global supply constraints [2]. - **Onboard Equipment**: The push for domestic onboard products is ongoing, with regulatory support from the Civil Aviation Administration of China (CAAC) to expedite the approval of key products [2]. - **Diverse Sector Involvement**: The industry encompasses various segments, including engines, onboard equipment, landing gear, and airframe structures, with numerous companies involved across these categories [2]. This summary encapsulates the key insights and developments within the domestic large aircraft sector as discussed in the conference call records.

证券代码：000534 证券简称：万泽股份 公告编号:2026-007 万泽实业股份有限公司 关于控股股东持股比例变动超过 1%的公告 万泽集团 2025 年面向专业投资者非公开发行科技创新可交换公司债券 （第一期）（债券简称：25 万泽 KEB1、25 万泽 KEB2）以本公司股票为标 的，于 2025 年 11 月 24 日进入换股期，换股期限为 2025 年 11 月 24 日至 2028 年 5 月 19 日止。具体内容详见公司于 2025 年 11 月 19 日披露的《关 于控股股东可交换公司债券进入换股期的提示性公告》（公告编号： 2025-098）。 万泽集团 2025 年面向专业投资者非公开发行科技创新可交换公司债券 （第二期）（债券简称：25 万泽 KEB3、25 万泽 KEB4）以本公司股票为标 1 的，于 2026 年 1 月 12 日进入换股期，换股期限为 2026 年 1 月 12 日至 2028 年 7 月 7 日止。具体内容详见公司于 2026 年 1 月 6 日披露的《关于控股股 东可交换公司债券进入换股期的提示性公告》（公告编号：2026-001）。 公司于 2026 年 1 ...

Market Overview - The biopharmaceutical sector increased by 1.27% on February 3, with Wanzhe Co., Ltd. leading the gains [1] - The Shanghai Composite Index closed at 4067.74, up 1.29%, while the Shenzhen Component Index closed at 14127.1, up 2.19% [1] Stock Performance - Wanzhe Co., Ltd. (000534) closed at 30.65, with a rise of 10.01% and a trading volume of 313,500 shares, amounting to a transaction value of 921 million yuan [1] - Other notable performers included ST Weiming (002581) with a 5.01% increase, closing at 7.55, and Nearshore Protein (688137) with a 4.84% increase, closing at 44.20 [1] Capital Flow - The biopharmaceutical sector experienced a net outflow of 255 million yuan from institutional investors and 153 million yuan from retail investors, while retail investors saw a net inflow of 408 million yuan [2] - The capital flow for individual stocks showed that Wanzhe Co., Ltd. had a net outflow of 50.83 million yuan from institutional investors, while retail investors contributed a net inflow of 15.59 million yuan [3] Individual Stock Analysis - Eurolin Biotech (688319) had a net inflow of 21.61 million yuan from institutional investors, while ST Weiming (002581) saw a significant net inflow of 13.51 million yuan [3] - Conversely, major outflows were noted in Wanzhe Co., Ltd. and other stocks, indicating varied investor sentiment across the sector [3]

中国经济网北京1月29日讯万泽股份（000534）(000534.SZ)昨日晚间披露关于控股股东持股比例变动达到 1%的公告称，公司的控股股东万泽集团有限公司(以下简称"万泽集团")2023年面向专业投资者非公开发行 可交换公司债券(第一期)品种二(债券简称：23万泽EB02)以公司股票为标的，于2024年5月27日进入换股 期，换股期限为2024年5月27日起至2026年11月23日。 | 股份种类(A 股、B 股 | 增持/减持股数(万股) | 增持/减持比例(%) | | --- | --- | --- | | 等) | | | | A 股 | 506.7920 | 1.00 | | 合 计 | 506.7920 | 1.00 | 2026年1月20日至2026年1月27日，万泽股份的加权均价为27.21元，以此计算，万泽集团及其一致行动人套 现约1.38亿元。 万泽集团2025年面向专业投资者非公开发行科技创新可交换公司债券(第一期)(债券简称：25万泽KEB1、25 万泽KEB2)以公司股票为标的，于2025年11月24日进入换股期，换股期限为2025年11月24日至2028年5月19 日止。万泽集 ...

Group 1 - The core point of the news is that Wanzhou Co., Ltd. has seen a significant increase in its stock price, rising 5.04% to 32.51 yuan per share, with a total market value of 16.565 billion yuan and a cumulative increase of 13.79% over the past three days [1] - Wanzhou Co., Ltd. was established on November 4, 1992, and listed on January 10, 1994. The company specializes in the research, production, and sales of micro-ecological preparations and high-temperature alloys [1] - The main revenue composition of Wanzhou Co., Ltd. includes: Jindouqi (48.91%), high-temperature alloy material sales (26.30%), Dingjunsheng (23.12%), and others (1.27%) [1] Group 2 - Longxin Fund's Longxin National Defense and Military Industry Quantitative Mixed A Fund (002983) has entered the top ten circulating shareholders of Wanzhou Co., Ltd., holding 11.7722 million shares, accounting for 2.35% of circulating shares [2] - The Longxin National Defense and Military Industry Quantitative Mixed A Fund has achieved a year-to-date return of 12.23% and a one-year return of 74.65% [2] - The fund manager, Song Haian, has a tenure of 7 years and 354 days, with the best fund return during this period being 209.97% [3]

证券代码：000534 证券简称：万泽股份 公告编号:2026-006 万泽实业股份有限公司 关于控股股东持股比例变动达到 1%的公告 公司控股股东万泽集团有限公司保证向本公司提供的信息内容真实、准 确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、控股股东持股变动原因 万泽实业股份有限公司（以下简称"公司"或"本公司"）的控股股东 万泽集团有限公司（以下简称"万泽集团"）2023 年面向专业投资者非公开 发行可交换公司债券（第一期）品种二（债券简称：23 万泽 EB02）以本公 司股票为标的，于 2024 年 5 月 27 日进入换股期，换股期限为 2024 年 5 月 27 日起至 2026 年 11 月 23 日。具体内容详见公司于 2024 年 5 月 21 日披露 的《关于控股股东可交换公司债券进入换股期的提示性公告》（公告编号： 2024-043）。 | 通过证券交易所的集中交易 | 通过证券交易所的大宗交易 □ | | | □ | | | | | --- | --- | --- | --- | - ...

Group 1 - The biopharmaceutical sector experienced a decline of 1.98% on January 28, with Baipusais leading the drop [1] - The Shanghai Composite Index closed at 4151.24, up 0.27%, while the Shenzhen Component Index closed at 14342.9, up 0.09% [1] - Notable gainers in the biopharmaceutical sector included Kanghua Biological, which rose by 3.02% to a closing price of 74.70, and Liaoning Chengda, which increased by 2.55% to 12.86 [1] Group 2 - Baipusais saw a significant drop of 10.57%, closing at 58.18, with a trading volume of 57,400 shares and a transaction value of 342 million [2] - Other notable decliners included Kangla Weishi, down 6.16% to 10.97, and Jinchuan Protein, down 5.90% to 46.58 [2] - The biopharmaceutical sector experienced a net outflow of 1.252 billion in main funds, while retail investors saw a net inflow of 653 million [2] Group 3 - Rongchang Biological had a net inflow of 38 million from main funds, representing 6.49% of its total, while it faced a net outflow of 58.99 million from retail investors [3] - Liaoning Chengda also saw a net inflow of 14.86 million from main funds, but a net outflow of 15.01 million from retail investors [3] - The overall trend indicates a mixed sentiment in the biopharmaceutical sector, with main funds withdrawing while retail investors are actively buying [3]

Market Overview - The biopharmaceutical sector experienced a decline of 0.7% on January 27, with the nearshore protein leading the drop [1] - The Shanghai Composite Index closed at 4139.9, up 0.18%, while the Shenzhen Component Index closed at 14329.91, up 0.09% [1] Top Gainers in Biopharmaceutical Sector - Hualan Ting (301207) saw a closing price of 26.05, with a significant increase of 11.61% and a trading volume of 563,900 shares, totaling a transaction value of 1.421 billion yuan [1] - Sanofi Guojian (688336) closed at 63.53, up 10.93%, with a trading volume of 201,400 shares and a transaction value of 1.270 billion yuan [1] - Wanzhe Co. (000534) closed at 30.80, increasing by 8.45%, with a trading volume of 318,400 shares and a transaction value of 958 million yuan [1] Top Decliners in Biopharmaceutical Sector - Nearshore Protein (688137) closed at 49.50, down 6.95%, with a trading volume of 39,100 shares and a transaction value of 192 million yuan [2] - Watson Bio (300142) closed at 13.49, decreasing by 6.84%, with a trading volume of 1,628,800 shares and a transaction value of 2.193 billion yuan [2] - Sanyuan Gene (920344) closed at 25.37, down 6.52%, with a trading volume of 32,200 shares and a transaction value of 81.8541 million yuan [2] Capital Flow Analysis - The biopharmaceutical sector experienced a net outflow of 821 million yuan from institutional investors, while retail investors saw a net inflow of 243 million yuan [2] - The sector's overall capital flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors are actively buying [2] Individual Stock Capital Flow - Junshi Biosciences (688180) had a net inflow of 1.93 million yuan from institutional investors, but saw a net outflow of 9.328 million yuan from speculative funds [3] - Wanzhe Co. (000534) experienced a net inflow of 51.5191 million yuan from institutional investors, with a net outflow of 1.2819 million yuan from speculative funds [3] - Zhixiang Jintai (688443) had a net inflow of 18.0619 million yuan from institutional investors, while speculative funds saw a net outflow of 636.35 million yuan [3]